Yakup Ergün· @dr_yakupergun · X·· 1 天前评分70
正文 · 原文
#ESMO26 | VIKTORIA-1 –Study 2— Updated Results
In PIK3CA-mutant HR+/HER2− advanced breast cancer, gedatolisib + fulvestrant + palbociclib maintained its PFS benefit over alpelisib + fulvestrant (9.8 vs 5.6 months; HR 0.52). Median PFS was 11.1 months at ASCO26.
The benefit was observed with and without visceral metastases (HR 0.38 and 0.46, respectively).
The contribution of palbociclib remains unclear, and IV administration continues to be a practical limitation.
613 浏览 · 10 赞 · 3 转发 · 0 回复
会议摘要
LBA16按 Rapid oral 1: Breast cancer, advanced stage 对上
VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)
https://esmocongress.esmo.org来源：Yakup Ergün · x.com